Compass Pathways Plc ADR (NASDAQ:CMPS)’s traded shares stood at 0.5 million during the latest session, with the company’s beta value hitting 2.30. At the last check today, the stock’s price was $4.14, to imply an increase of 11.89% or $0.44 in intraday trading. The CMPS share’s 52-week high remains $12.75, putting it -207.97% down since that peak but still an impressive 23.67% since price per share fell to its 52-week low of $3.16.
Analysts have given a consensus recommendation of Buy for Compass Pathways Plc ADR (CMPS), translating to a mean rating of 1.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give CMPS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.64.
Compass Pathways Plc ADR (NASDAQ:CMPS) trade information
After registering a 11.89% upside in the latest session, Compass Pathways Plc ADR (CMPS) has traded red over the past five days. The 5-day price performance for the stock is -8.81%, and 5.08% over 30 days. With these gigs, the year-to-date price performance is 9.52%.
The extremes give us $23 and $23 for target low and target high price respectively. As such, CMPS has been trading -455.56% off suggested target high and -455.56% from its likely low.
CMPS Dividends
Compass Pathways Plc ADR has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is TCG CROSSOVER MANAGEMENT, LLC with 3.86 million shares, or about 5.6427% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $23.3 million.
We also have ARK ETF Tr-ARK Genomic Revolution ETF and iShares Biotechnology ETF as the top two Mutual Funds with the largest holdings of the Compass Pathways Plc ADR (CMPS) shares. Going by data provided on Dec 31, 2024 , ARK ETF Tr-ARK Genomic Revolution ETF holds roughly 1.71 shares. This is just over 1.85% of the total shares, with a market valuation of $7.03 million. Data from the same date shows that the other fund manager holds a little less at 360.99, or 0.39% of the shares, all valued at about 1.48 million.
